Apixabanisahighlyselective,reversibleinhibitorofFactorXawithK_iof0.08nMand0.17nMinhumanandrabbit,respectively.

IC50:0.08nM(HumanFactorXa),0.17nM(RabbitFactorXa)

Apixabanexhibitsahighdegreeofpotency,selectivity,andefficacyonFactorXawithK_iof0.08nMand0.17nMforHumanFactorXaandRabbitFactorXa,respectively^[1].Invitro,Apixabanprolongstheclottingtimesofnormalhumanplasmawiththeconcentrations(EC2x)of3.6μM,0.37μM,7.4μM,and0.4μM,whicharerequiredrespectivelytodoubletheprothrombintime(PT),modifiedprothrombintime(mPT),activatedpartialthromboplastintime(APTT)andHepTest.Besides,Apixabanshowsthehighestpotencyinhumanandrabbitplasma,butlesspotencyinratanddogplasmainboththePTandAPTTassays^[2].

Apixabanshowstheexcellentpharmacokineticswithverylowclearance(Cl:0.02L/kg/h),andlowvolumeofdistribution(Vdss:0.2L/kg)inthedogs.Besides,Apixabanalsoexhibitsamoderatehalf-life(T1/2:5.8hours)andgoodoralbioavailABIlity(F:58%)^[1].Inthearteriovenous-shuntthrombosis(AVST),venousthrombosis(VT)andelectricallymediatedcarotidarterialthrombosis(ECAT)rabbitmodels,Apixabanproducesdose-dependentantithromboticeffectswithEC₅₀of270nM,110nMand70nM,respectively^[2].ApixabansignificantlyinhibitsfactorXaactivitywithIC₅₀of0.22μMinrabbitexvivo^[3].Inchimpanzee,Apixabanalsoshowssmallvolumeofdistribution(Vdss:0.17L/kg),lowsystemicclearance(Cl:0.018L/kg/h),andgoodoralbioavailability(F:59%)^[4].

• [1].PintoDJ,etal.Discoveryof1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide(apixaban,BMS-562247),ahighlypotent,selective,efficacious,andorallybioavailableinhibitorofblo

  [2].WongPC,etal.Apixaban,anoral,directandhighlyselectivefactorXainhibitor:invitro,antithromboticandantihemostaticstudies.JThrombHaemost.2008May;6(5):820-9.

  [3].ZhangD,etal.Metabolism,pharmacokineticsandpharmacodynamicsofthefactorXainhibitorapixabaninrabbits.JThrombThrombolysis.2010Jan;29(1):70-80.

  [4].HeK,etal.Preclinicalpharmacokineticsandpharmacodynamicsofapixaban,apotentandselectivefactorXainhibitor.EurJDrugMetabPharmacokinet.2011Sep;36(3):129-39.

PurifiedFXaisobtainedafteractivationwithRussell’svipervenomfollowedbyaffinitychromatography.TheresultingFXais>95%pureasjudgedbysodiumdodecylsulfatepolyacrylamidegelelectrophoresis.ThesubstrateaffinityvaluesforFXa,expressedastheMichaelis-Menten-Henriconstant(K_m),forhuman,rabbit,ratanddogFXaaredeterminedusingthechromogenicsubstrateS-2765,andare36,60,240and70μM,respectively.Thesubstratehydrolysisismonitoredbymeasuringabsorbanceat405nmat25°Cforupto30minusingaSpectraMax384PlusplatereaderandSoftMax.FXaactivityforeachsubstrateandinhibitorconcentrationpairisdeterminedinduplicate.TheK_ivaluesarecalculatedbynon-linearleast-squaresfittingofthesteady-statesubstratehydrolysisratestotheequationforcompetitiveinhibition(Equation1)usingGRAFIT,wherevequalsreactionsvelocityinODmin−1,Vmaxequalsmaxiumumreactionvelocity,Sequalssubstrateconcentration,andIequalsinhibitorconcentration.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.

Apixabanisformulatedinvehicle(10%N,N-dimethylacetamide;30%1,2-propanediol;60%water).

Briefly,maleNewZealandWhiterabbitsareanesthetizedwithketamine(50mg/kgi.m.)andxylazine(10mg/kgi.m.),andtheirfemoralartery,jugularveinandfemoralveinarecatheterized.Theseanestheticsaresupplementedasneeded.Thrombosisisinducedbyanarteriovenous(AV)-shuntdevicecontainingasilkthread.BloodflowedfromthefemoralarteryviatheAVshuntintotheoppositefemoralveinfor40min.Theshuntisthendisconnectedandthesilkthreadcoveredwiththrombusisweighed.Asapixabanhasanoralbioavailabilityof<5%=""in=""rabbits=""(unpublished=""result),=""it=""is=""administered=""intravenously=""for=""in=""vivo=""studies.=""to=""achieve=""a=""stable=""plasma=""level=""with=""minimum=""experimental=""variability,=""apixaban,=""fondaparinux=""or=""vehicle=""is=""given=""by=""a=""continuous=""intravenous=""infusion=""1=""h=""prior=""to=""shunt=""placement.=""the=""infusion=""is=""continued=""throughout=""the=""experiment.=""warfarin=""or=""vehicle=""is=""dosed=""orally=""once=""daily=""for=""4=""days.=""on=""the=""fourth=""day=""after=""the=""last=""oral=""dose=""of=""warfarin=""or=""vehicle,=""rabbits=""are=""anesthetized=""1.5=""h=""later,=""and=""the=""treatment=""effect=""is=""evaluated=""about=""2=""h=""postdose.=""arterial=""blood=""samples=""for=""the=""determination=""of=""clotting=""times=""or=""plasma=""levels=""are=""collected=""20=""min=""after=""shunt=""placement.=""plasma=""levels=""of=""apixaban=""are=""measured=""by=""a=""specific=""and=""sensitive=""liquid=""chromatographic=""mass=""spectrometry=""method=""(lc/ms/ms).=""in=""rabbits=""treated=""with=""apixaban,=""fondaparinux=""or=""warfarin,=""the=""antithrombotic=""effects=""of=""these=""agents=""are=""expressed=""as=""percentage=""inhibition=""of=""thrombus=""formation=""based=""on=""the=""treated=""vs.=""the=""corresponding=""mean=""vehicle.=""the="">₅₀value(dosethatproduced50%inhibitionofthrombusformation)isdeterminedasdescribedbelow.Theapixabangrouptreatmentconsistsofvehicle(10%N,N-dimethylacetamide;30%1,2-propanediol;60%water)(n=4),andapixaban(mg/kg/h)at0.03(n=7),0.1(n=7),0.3(n=7),1(n=7),and3(n=3).Thefondaparinuxgrouptreatmentconsistsofvehicle(saline)(n=6),andfondaparinux(mg/kg/h1)at0.01(n=5),0.03(n=5),0.1(n=5),0.3(n=5),and1(n=5).Thewarfaringrouptreatmentconsistsofvehicle(water)(n=6),andwarfarin(mg/kg/day)at0.1(n=6),0.3(n=6),1(n=6),and3(n=6).MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.

• [1].PintoDJ,etal.Discoveryof1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide(apixaban,BMS-562247),ahighlypotent,selective,efficacious,andorallybioavailableinhibitorofblo

  [2].WongPC,etal.Apixaban,anoral,directandhighlyselectivefactorXainhibitor:invitro,antithromboticandantihemostaticstudies.JThrombHaemost.2008May;6(5):820-9.

  [3].ZhangD,etal.Metabolism,pharmacokineticsandpharmacodynamicsofthefactorXainhibitorapixabaninrabbits.JThrombThrombolysis.2010Jan;29(1):70-80.

  [4].HeK,etal.Preclinicalpharmacokineticsandpharmacodynamicsofapixaban,apotentandselectivefactorXainhibitor.EurJDrugMetabPharmacokinet.2011Sep;36(3):129-39.

459.5

C₂₅H₂₅N₅O₄

503612-47-3

RoomtemperatureincontinentalUS;mayvaryelsewhere

DMSO:14.25mg/mL;H₂O：<0.1="">

*"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">

Purity:99.97%

SelectBatch:HY-50667-26132HY-50667-21738HY-50667-21795HY-50667-09783

DataSheet(124KB)SDS(120KB)

COA(94KB)RP-HPLC(137KB)

HandlingInstructions(1252KB)

• [1].PintoDJ,etal.Discoveryof1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide(apixaban,BMS-562247),ahighlypotent,selective,efficacious,andorallybioavailableinhibitorofblo

  [2].WongPC,etal.Apixaban,anoral,directandhighlyselectivefactorXainhibitor:invitro,antithromboticandantihemostaticstudies.JThrombHaemost.2008May;6(5):820-9.

  [3].ZhangD,etal.Metabolism,pharmacokineticsandpharmacodynamicsofthefactorXainhibitorapixabaninrabbits.JThrombThrombolysis.2010Jan;29(1):70-80.

  [4].HeK,etal.Preclinicalpharmacokineticsandpharmacodynamicsofapixaban,apotentandselectivefactorXainhibitor.EurJDrugMetabPharmacokinet.2011Sep;36(3):129-39.

品牌介绍

托烷司琼临床评价药物相关作用适应症托烷司琼CAS号:89565-68-4英文名称:Tropisetron英文同义词:icf205-930;TROPICACID;TROPISETRON;SS-TROPISETRON;BETA-TROPISETRON;Tropisetron(ICS205930);TROPISHTRONHYDROCHLORIDE;Indole-3-carbonylchloride;3-Tropanylindole-3-carboxylate;lαH，5Αh-Tropan-3α-ylindole-3-carboxylate中文名称:托烷司琼中文同义词:托普西隆;托普西龙;曲匹西龙;托烷司琼;Β-托烷司琼;CS-348;Β-内托烷司琼;吲哚-3-甲酰氯;Β-托烷司琼(光学异构体);Β-托烷司琼,托烷司琼异构体CBNumber:CB3236404分子式:C17H20N2O2分子量:284.35MOLFile:89565-68-4.mol化学性质安全信息用途供应商112化学性质安全信息用途供应商112托烷司琼化学性质熔点:201-202°C沸点:448.5±35.0°C(Predicted)密度:1.26储存条件:2-8°C溶解度:H2O:soluble形态:solid酸度系数(pKa):15.38±0.30(Predicted)颜色:whiteCAS数据库:Chemicalbook89565-68-4(CASDataBaseReference)安全信息WGKGermany:3托烷司琼化学药品说明书托烷司琼|药物应用信息托烷司琼性质、用途与生产工艺临床评价Sorbe等报道本品对含顺铂(剂量50～89mg/m2)化疗方案引起的急性呕吐完全控制率为63%。58例恶性肿瘤化疗所致恶心、呕吐者，应用托烷司琼或昂丹司琼8mg分别在同一病人前后2个化疗周期的第1d给药前30min静脉注射，并用地塞米松10mg静脉滴注。结果两药控制急性及迟发性恶心、呕吐的疗效基本相似，均可达81%～100%。本品对强致吐化疗药物顺铂的止吐疗效突出。药物相关作用饮食可略为延长本品的吸收。本品与利福平、苯巴比妥等肝酶诱导药同时使用，可加快代谢，故快代谢型者需增加剂量，慢者则不必。西咪替丁等肝酶抑制药对本品血药浓度无明显影响。适应症托烷司琼临床用于预防和治疗癌症化疗引起的恶心和呕吐。化学性质结晶，熔点201-202℃(二氯甲烷-乙酸乙酯)。单盐酸托烷司琼(TropisetronMonohydroehloride)：C17H20N2O2?HCI。[105826-92-4]。熔点283-285℃(分解)。用途有高效性和选择性的5-HT3受体拮抗剂。用于化疗所致的呕吐。用途为5-羟色胺拮抗药生产方法托品醇(I)和酰氯(Ⅱ)反应，可得托烷司琼。托烷司琼上下游产品信息上游原料托品醇下游产品

公司介绍

托烷司琼临床评价药物相关作用适应症托烷司琼CAS号:89565-68-4英文名称:Tropisetron英文同义词:icf205-930;TROPICACID;TROPISETRON;SS-TROPISETRON;BETA-TROPISETRON;Tropisetron(ICS205930);TROPISHTRONHYDROCHLORIDE;Indole-3-carbonylchloride;3-

品牌分类

黄酮类化合物 抑制性抗体 苯丙素类 酸和醛 醌类 肽 其他 酚类 萜类和糖苷类

类固醇 生物碱 糖类和糖苷类 染料试剂 生化分析试剂

显示分类

联络我们

服务热线：4000-520-616

（限工作日9:00-18:00）

QQ ：1570468124

手机：18915418616

官网：http://www.medchemexpress.com/

快速导航：

公司介绍

产品中心

新闻动态

在线咨询

联系我们

公司介绍

产品中心

新闻动态

在线咨询

联系我们

总部地址：

江苏省苏州市工业园区星湖街218号 苏州生物医药产业园一期（生物纳米园）A4-216(邮编：215125)

工作时间：周一至周五9:00~18:00

技术支持：

Email：info@ebiomall.com

短信：18915418616

服务热线：

4000-520-616（全国）

☏  0512-67156496（苏州）

版权信息：

©  2015-2022 苏州蚂蚁淘生物科技有限公司 版权所有 中国

网站备案：

苏ICP备17049038号-1

苏公网安备 32059002001627号

友情链接：

联系QQ:764052152

medix采购 medkoo正品 megazyme清关 microspheres报价 midlandsci代购 minerva官网 molecular molinnov moltox mpbio relassay中国 Polysciences说明书 electronmicroscopysc Viskase apgm华东代理 美国LKT Labs imgenexindia代理 蚂蚁淘 广东众鑫实验室设备有限公司

免责声明：

本站有部分内容来自互联网，如无意中侵犯了某个媒体 、公司 、企业或个人等的知识产权，请来电或致函告之，
本网站将在规定时间内给予删除等相关处理。

扫描二维码关注官方微信

获取最新促销及产品信息